Attendee list released for Orphan Drugs & Rare Diseases 2016!

SMi Reports (13.09.2016, London, UK): Alexion, BioMarin, Chiesi, MHRA, NICE to meet in London in October to discuss updates in the orphan drug landscape

A preliminary list of delegates for SMi’s 5th Orphan Drugs & Rare Diseases Conference has been released. Representatives from over 30 organisations shaping up the orphan drug landscape will gather at the two-day event which takes place on 19 & 20 October in Central London.

Confirmed attendees include industry experts from Abeona, AKU Society, Alexion, BioMarin, Boehringer Mannheim, Chiesi, ClinTec International, Findacure, INC Research, Mereo BioPharma, MHRA, NICE, Quintiles, Shire, The Birmingham Children’s Hospital, and many more. The full list of delegates can be viewed on the event website at

This year’s programme will feature 20+ industry-led and case-study driven presentations, a panel discussion plus two interactive pre-conference workshops.

Teaming up with key movers and shakers within the industry, SMi has tailored the conference programme to bring up key topics such as strategies to accelerate orphan drug development; market access, pricing and reimbursement; addressing challenges in defending orphan drugs pricing; patient groups’ perspectives on patient recruitment and retention; gene and cell therapy treatments; and regulatory updates for orphan products with a focus on emerging markets.

The event will also feature two interactive workshops: “Planning for success: Developing the optimal orphan drug development strategy” led by Cell Medica and Chiesi and “Paving the way for achieving orphan drug market access” led by RJW & Partners.

A detailed programme is available to view on the event website.

For those interested in attending Orphan Drugs 2016, registration is live online at

5th Orphan Drugs & Rare Diseases Conference and Exhibition
19-20 October 2016, London UK

375 x 375 copy

Partnership with Genetic Insider! International Molecular Diagnostics Congress, 14-15 Sept

Personalize My Medicine is partnering with Genetic Insider and their International Molecular Diagnostics Congress!

The Congress is the first commercially focused event for companion diagnostics.

  • Feel the buzz of bringing together 100+ passionate diagnostics and personalized medicine professionals
  • Become truly confident that your company is well-known within the industry and compare your strategy with the best practices presented
  • Get first-hand advice on how to finance your company and accelerate market access with disruptive business models and hear about the latest trends and developments in this field!

Download the brochure for more information:

Register here:


See you at the Precision Medicine Congress 2016!

Precision Medicine 2016 700x

Leading industry insights from precision medicine professionals

This May 18th, London will welcome over 30 leading international speakers to the inaugural World Precision Medicine Congress. Ahead of then conference organisers, Terrapinn, wanted to give you a taste of what you will hear on-site with some exclusive insights from some of these esteemed thought-leaders.

Click here to read the full speaker interviews as part of the Industry Insights eBook.

The past year has highlighted both challenges in the areas of big data and healthcare uptake, but also shown the great potential this medical approach has in areas of unmet medical need, notably rare diseases.

Terrapinn spoke to their revered speaker faculty to find out what they thought had been the biggest achievement in their respective industries over the last 12 months. Niven Narain, Co-Founder, President & CEO of Berg Health notes that “over the past year we have seen the initiation of industry, government, and academic collaborations to create a dialogue around precision medicine”. Yiu-Lian Fong, Senior Director for Global Diagnostic Innovation at Johnson & Johnson pInnovation credits the biggest achievement to be “President Obama’s launch of the Precision Medicine Initiative (PMI) with a budget of $215 million in fiscal year 2016 and development of the framework for NIH’s Precision Medicine Initiative Cohort Program to enrol 1 million or more Americans to expand our knowledge and practice of precision medicine”.

In terms of challenges in the implementation of precision medicine, Victoria Rimkunas, Head of the Integrated Diagnostics Lab at Merrimack Pharmaceuticals thinks that the biggest difficulty has been in “disparities in patient access to high quality diagnostics that are being used to inform their care”.

They were also asked for their opinions on what disease area they thought held the most potential for treatment or cure within the precision medicine sector. Peter Johnson, Chief Clinician at Cancer Research UK considers that “cancer treatment will continue to lead the way in this: as oncologists we have so much information about the molecular landscape of cancers and such a diverse pipeline of novel therapeutics to bring to bear on the problem”.

Amongst the questions asked to the speakers, Terrapinn wanted to find out who, either a person or company, they thought would be ‘the next big thing’. The responses were very much determined by which therapeutic field they were most interested in but Tony Freemont, Head of the MRC/ESRC Molecular Pathology Node in Manchester thinks it will “not [be] a company we have currently heard of, because the next great application will come from people thinking way outside the box”.

Finally the speaker interviews were concluded by asking them all what they think will be the biggest topic of discussion at this year’s event. Alastair Kent, Director at Genetic Alliance UK put forward his view that it would likely be “pricing and patient access”.

To read the full speaker interviews, as well as many more, click here to download the Industry Insights eBook now.

Conference Manager, Hannah Yates, was also asked her thoughts ahead of the event on 18-19 May at the Business Design Centre in Angel, London. “For the precision medicine sector to really reach its potential, we think it is key to bring together industry, healthcare and academia from across the variety of disciplines included under the precision medicine umbrella and from across the globe. The World Precision Medicine Congress is truly a global forum for this industry, alongside the co-located cell and gene conference, and I look forward to seeing you all there”.

To register your discounted place, please click here.

Partnership with EuroSciCon and Life Science Events

Personalize My Medicine is pleased to announce a partnership with EuroSciCon!

Founded in 2001 by Dr Shara Cohen after identifying a need for communicating science research between academia, clinical practice,  and industry, EuroSciCon’s Life Science Events provide an environment to interact and debate, both online and at highly focused, informal events. All our unbiased events are in an informal setting,  allowing for maximum networking and interactions with all participants from many fields.  Each event is an opportunity for industry, clinical practice, and academia to share, discuss, and create new bonds and new ideas for the future. Our multi-professional and multi-speciality approach creates a unique experience that cannot be found with a specialist society or commercially.

Partnership with RareCare

Personalize My Medicine is pleased to announce a partnership with RareCareUK!

RareCareUK aims to supply care when it is lacking through the normal channels.
‘Being told you or a child has a rare disease is not only devastating from the view that there is an illness, but this devastation is compounded by the knowledge that your care and hope are limited.  RareCareUK will provide care for now, hope for future, and the ability to play a role in achieving this’- Dr Shara Cohen, Founder of RareCareUK
Rare Care UK Logo